Publication:
Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder

Placeholder

Organizational Units

Authors

Köle, İsmail Hasan
Vural, Pınar
Yurdacan, Beste
Alemdar, Adem
Mutlu, Caner

Advisor

Language

Publisher:

Springer Heidelberg

Journal Title

Journal ISSN

Volume Title

Abstract

Background There is insufficient replicated data to establish a relationship between the polymorphisms of SLC6A2 and CYP2D6 and the treatment responses of atomoxetine (ATX) in ADHD. We focused on evaluating the effect of top-line single nucleotide polymorphisms (SNPs) in SLC6A2 and CYP2D6 on the ATX treatment response in attention deficit and hyperactivity disorder (ADHD). Methods Of 160 patient records, 34 patients who met the inclusion criteria were evaluated to determine the relationship between genotypes of ten SNPs (six of SLC6A2 and four of CYP2D6) and ATX treatment response. Additionally, the connection between SNPs of CYP2D6 and the severity of side effects associated with ATX was analyzed in 37 patients, including the 34 study patients, and three patients discontinued because of ATX-dependent side effects. Results All six polymorphisms we studied in SLC6A2 were associated with the treatment response of ATX. Clinical improvement in oppositional defiant disorder symptoms of patients with ADHD was only observed in carriers of the homozygous "C" allele of rs3785143 (p(odd) = 0.026). We detected an association between higher CGI-side-effect severity scores and the "TT" genotype of rs1065852 polymorphism in CYP2D6 (p = 0.043). Conclusions The findings of this study suggest that genotypes of polymorphisms within the SLC6A2 and CYP2D6 may play an influential role in treatment response or the severity of side effects associated with ATX in ADHD patients.

Description

Source:

Keywords:

Keywords

Norepinephrine transporter gene, Deficit/hyperactivity disorder, Methylphenidate response, Clinical-response, Children, Association, Adolescents, Variants, Atomoxetine, Attention deficit and hyperactivity disorder, Genetic polymorphism, CYP2D6 , Genetic polymorphism, SLC6A2, Pharmacology & pharmacy

Citation

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details